{
  "source": "PA-Med-Nec-Zeposia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2264-8\nProgram Prior Authorization/Medical Necessity\nMedication Zeposia® (ozanimod)\nP&T Approval Date 12/2021, 5/2022, 1/2023, 4/2023, 4/2024, 10/2024, 11/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nZeposia® (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the\ntreatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated\nsyndrome, relapsing-remitting disease, and active secondary progressive disease, in adults\nand moderately to severely active ulcerative colitis (UC) in adults.\n2. Coverage Criteriaa:\nA. Multiple Sclerosis\n1. Authorization\na. Zeposia will be approved based on the following criterion:\n(1) Diagnosis of multiple sclerosis (MS)\nAuthorization will be issued for 12 months.\nB. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Zeposia will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active UC\n-AND-\n(2) One of the following:\n(a) Patient has had prior or concurrent inadequate response to a therapeutic\ncourse of oral corticosteroids and/or immunosuppressants (e.g.,\nazathioprine, 6-mercaptopurine)\n-OR-\n(b) Patient has been previously treated with a biologic or targeted synthetic\nDMARD FDA-approved for the treatment of ulcerative colitis as\ndocumented by claims history or submission of medical records (Document\ndrug, date, and duration of therapy) [e.g., adalimumab, Simponi\n© 2025 UnitedHealthcare Services, Inc.\n1\n(golimumab), ustekinumab, Xeljanz (tofacitinib), Rinvoq (upadacitinib)].\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to two of the following\npreferred products (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsb\nii. Entyvio (vedolizumab)\niii. Omvoh (mirikizumab-mrkz)\niv. Rinvoq (upadacitinib)\nv. Simponi (golimumab)\nvi. Skyrizi (risankizumab)\nvii. One of the preferred ustekinumab productsb\nvi",
    "limumab productsb\nii. Entyvio (vedolizumab)\niii. Omvoh (mirikizumab-mrkz)\niv. Rinvoq (upadacitinib)\nv. Simponi (golimumab)\nvi. Skyrizi (risankizumab)\nvii. One of the preferred ustekinumab productsb\nviii. Tremfya (guselkumab)\nix. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Zeposia therapy as documented by claims history\nor submission of medical records (Document drug, date, and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Bristol Myers\nSquibb sponsored Zeposia 360 Support Program (e.g. sample card which\ncan be redeemed at a pharmacy for a free supply of medication) as a\nmeans to establish as a current user of Zeposia*\n-AND-\n(4) Patient is not receiving Zeposia in combination with a targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab,\nSkyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio\n(vedolizumab)]\n-AND-\n(5) Prescribed by or in consultation with a gastroenterologist\n*Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\n© 2025 UnitedHealthcare Services, Inc.\n2\nthe Bristol Myers Squibb sponsored Zeposia 360 Support Program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zeposia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Zeposia therapy\n-AND-\n(2) Patient is not receiving Zeposia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), ",
    "AND-\n(2) Patient is not receiving Zeposia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Cimzia\n(certolizumab), Simponi (golimumab), Orencia (abatacept), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), ustekinumab,\nSkyrizi (risankizumab), Omvoh (mirikizumab-mrkz), Entyvio (vedolizumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For a list of preferred products please reference drug coverage tools.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Zeposia [package insert]. Summit, NJ: Celegene Corporation; August 2023.\n2. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the\nmanagement of moderate to severe ulcerative colitis. Gastroenterology. 2020; 158(5):1450-61.\nProgram Prior Authorization/Medical Necessity – Zeposia® (ozanimod)\nChange Control\n12/2021 New program.\n5/2022 Added Xeljanz and Rinvoq as preferred products for failure,\ncontraindication, or intolerance for Ulcerative Colitis and added Rinvoq\nas an example of JAK inhibitor. Updated reference.\n1/2023 Updated step therapy requirements to Humira or Amjevita. Updated\nlisted examples from Humira to adalimumab.\n4/2023 Updated step therapy requirement from Humira or Amjevita to one of\nthe preferred adalimumab products and added the footnote “For a list of\n© 2025 UnitedHealthcare Services, Inc.\n3\npreferred adalimumab products please reference drug coverage tools.”\n4/2024 Annual review. Updated ",
    "d adalimumab products and added the footnote “For a list of\n© 2025 UnitedHealthcare Services, Inc.\n3\npreferred adalimumab products please reference drug coverage tools.”\n4/2024 Annual review. Updated not used in combination examples with no\nchange to clinical intent. Updated reference.\n10/2024 Updated step requirement noting Adalimumab-adaz (unbranded\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote. Added Entyvio, Omvoh and Skyrizi as step\ntherapy agents.\n11/2024 Added Tremfya as a step therapy agent.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the footnote “For a list of\npreferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}